Pfizer Halts Lung Cancer Trials Of Toll-Like Receptor Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
Fate of other oncology trials of the TLR9 candidate Pfizer licensed from Coley has not been made public.
You may also be interested in...
Pfizer Unveils Oncology Business Unit, Gives Failed Compounds Another Try
CHICAGO - With 22 oncology compounds in clinical studies, firm initiates two Phase III studies since Jan. 1; plans to start another five before year-end.
Pfizer Unveils Oncology Business Unit, Gives Failed Compounds Another Try
CHICAGO - With 22 oncology compounds in clinical studies, firm initiates two Phase III studies since Jan. 1; plans to start another five before year-end.
Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase
Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.